Loading stock data…
Surrozen, Inc. (SRZN)
$20.68-2.08 (-9.14%)
Market ClosedLast close Sep 8
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Surrozen, Inc. in the Healthcare sector is trading at $20.68 with a market capitalization of $243M. Wall Street consensus targets $44.80 (5 analysts), implying a +116.6% move over the next 12 months. The stock is currently 41% below its 52-week high of $35.00, remaining 14.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +116.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 27) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.00M | $5.00M↑ | $528,000↓ | $983,000 | $983,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.37M↑ | -$10.46M↑ | -$12.64M↓ | -$10.88M↓ | -$9.02M |
| Net Income | $50.18M↑ | -$127.50M↑ | -$183.16M↓ | -$71.64M↓ | $39.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including dis...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$243.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
151.89%
Volume
Today's trading volume
202,265
Recent News
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
Surrozen (NASDAQ:SRZN) Chief Executive Officer Craig Parker outlined the company’s rationale for developing Wnt-targeting retinal disease therapies during H.C. Wainwright’s 6th Annual Ophthalmology Investor Conference, emphasizing the company’s focus on Frizzled-4 signaling, anti-VEGF activity and,
We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Surrozen...
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Surrozen Conference: CEO Details Wnt-Fzd4 Eye Disease Bet, 2026 IND Plans for SZN-8141
Surrozen (NASDAQ:SRZN) Chief Executive Officer Craig Parker used a discussion at a 2026 investor summit to outline the company’s focus on Wnt pathway biology and antibody engineering, with an emphasis on retinal vascular diseases. Parker said Surrozen has worked on Wnt signaling since its founding i